Ridgeback Biotherapeutics LP
https://www.ridgebackbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ridgeback Biotherapeutics LP
Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
EU Crunch Time For Previously Rejected Lagevrio & Other New Drugs
MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.
Big Year Ahead For New Vir CEO De Backer
Having played a pivotal role in changing pharma strategy at Bayer, Marianne De Backer tells Scrip about her goal to turn Vir into an infectious disease powerhouse as the firm prepares for critical Phase II data readouts in hepatitis B and D, as well as flu.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice